OncoMatch/Clinical Trials/NCT04337606

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Is NCT04337606 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Chidamide and Decitabine for non hodgkin lymphoma.

Phase 1/2RecruitingChinese PLA General HospitalNCT04337606Data as of May 2026

Treatment: Chidamide · Decitabine · Camrelizumab — This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion. The purpose is to evaluate the safety and efficacy of the treatment with chidamide in combination with decitabine.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: car-t cell therapy

Lab requirements

Blood counts

adequate marrow function

Kidney function

adequate renal function

Liver function

adequate liver function

Cardiac function

adequate heart function

adequate marrow, live, renal and heart functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify